We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

HDL-Cholesterol Predicts Survival in Cirrhotic Patients with Gastrointestinal Bleeding

By LabMedica International staff writers
Posted on 10 Dec 2020
Image: Histopathology of a cirrhotic liver.  High-density lipoprotein cholesterol predicts survival in cirrhotic patients with acute gastrointestinal bleeding (Photo courtesy of Loyola University Chicago).
Image: Histopathology of a cirrhotic liver. High-density lipoprotein cholesterol predicts survival in cirrhotic patients with acute gastrointestinal bleeding (Photo courtesy of Loyola University Chicago).
Liver cirrhosis is an important cause of morbidity and mortality as a consequence of continuous liver injuries. Acute gastrointestinal bleeding is a serious complication and critical clinical event in cirrhotic patients. Hepatitis B virus (HBV) is the leading cause of liver cirrhosis in China.

Since the liver plays a crucial role in cholesterol homeostasis, hypercholesterolemia often occurs in patients with chronic liver diseases. The decrease in serum levels of lipids and lipoproteins is highly prevalent in cirrhotic patients, with a prevalence that increases in parallel with the disease severity.

Infectious disease specialists at the Peking University First Hospital (Beijing, China) evaluated from January 2008 to December 2015, consecutive cirrhotic patients with acute gastrointestinal bleeding who were randomly divided into the derivation (n = 629) and validation (n = 314) cohorts. Liver cirrhosis was confirmed either by liver biopsy or by clinical presentations, routine liver function tests and medical imaging techniques. A logistic regression model was established to confirm the association between lipoprotein cholesterol and mortality. Routine biochemical tests were performed in the hospital laboratory. Lipid profiles include triglyceride, cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C).

The investigators reported that on ROC analysis, HDL-C showed excellent diagnostic accuracy for six-week mortality, with an area under the receiver operating characteristic curves (AUROC) of 0.847 (95% CI 0.789–0.905). The best cut-off value of HDL-C was 0.54 mmol/L, with a sensitivity of 85.1% and specificity of 74.2%. The laboratory variables significantly associated with 6-week mortality in the univariate analysis were as follows: hepatocellular carcinoma (HCC), packed red blood cells (PRBC) transfusion, hemoglobin (HGB), total leukocyte count (WBC), alanine aminotransferase (ALT), serum sodium (Na), total bilirubin (TBIL), albumin (ALB), cholesterol, HDL-C, LDL-C, serum creatinine (Scr), international normalized ratio (INR), fibrinogen (FIB). Multivariate logistic regression analyses showed that TBIL, HDL-C, Na, and HGB were independently associated with six-week mortality.

The authors concluded that HDL-C is a potential indicator for the prognosis of patients with cirrhosis and acute gastrointestinal bleeding. The new algorithm based on HDL-C allowed an accurate predictive assessment of 6-week mortality after bleeding attack. The study was published on November 16, 2020 in the journal BMC Gastroenterology.


Related Links:
Peking University First Hospital

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more